EMPA-REG OUTCOME: The Nephrologist's Point of View

The American Journal of Medicine
Christoph Wanner

Abstract

There is increasing evidence that sodium glucose cotransporter 2 (SGLT2) inhibitors have renoprotective effects, as demonstrated by the renal analyses from clinical trials including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME), CANagliflozin Treatment And Trial Analysis versus SUlphonylurea (CANTATA-SU), and the dapagliflozin renal study. The potential mechanisms responsible are likely multifactorial, and direct renovascular and hemodynamic effects are postulated to play a central role. This report reviews the renal outcomes data from key SGLT2 inhibitor clinical trials, discusses the hypotheses for SGLT2 inhibitor-associated renoprotection, and considers the main renal safety issues associated with SGLT2 inhibitor treatment.

References

May 21, 2017·The American Journal of Medicine·James Thrasher

❮ Previous
Next ❯

Citations

May 21, 2017·The American Journal of Medicine·Son V Pham, Robert Chilton
Jul 19, 2018·American Journal of Physiology. Renal Physiology·K Melissa HallowDavid W Boulton
Jun 28, 2018·Drugs·James E Frampton
Feb 17, 2019·Archives of Pharmacal Research·Sungmi ParkIn-Kyu Lee
Apr 3, 2019·Kidney & Blood Pressure Research·Chang ChuBerthold Hocher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.